Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.
Ritonavir-boosted darunavir with efavirenz may be considered a nucleoside-sparing regimen for treatment-naïve HIV-infected patients. However, the pharmacokinetics of this combination administered once daily have not been studied. We conducted a three-period interaction study with healthy volunteers. The subjects were given darunavir at 900 mg with ritonavir at 100 mg once daily for 10 days. Efavirenz at 600 mg once daily was added for 14 days. Darunavir-ritonavir was then stopped and efavirenz alone was given for 14 days. At the end of each period, blood was taken predosing and for up to 24 h postdosing to measure the drug concentrations. We recruited seven males and five females ages 24 to 49 years and weighing 50 to 83 kg. The darunavir trough concentrations were reduced after efavirenz administration (geometric mean ratio [GMR], 0.43; 90% confidence interval [CI], 0.32 to 0.57]; P < 0.001). The mean darunavir trough concentrations were 1,180 ng/ml (standard deviation, 1,138 ng/ml) after efavirenz administration, but all darunavir trough concentrations were above the 50% effective concentration (EC(50)) of 55 ng/ml for the wild-type virus. For darunavir, the area under the concentration-time curve from 0 to 24 h (AUC(0-24)) (GMR, 0.86; 90% CI, 0.75 to 0.97; P = 0.05) and the half-life (GMR, 0.56; 90% CI, 0.49 to 0.65; P < 0.001) were also significantly reduced. The darunavir peak concentrations were not significantly changed (GMR, 0.92; 90% CI, 0.82 to 1.03; P = 0.23). The ritonavir trough concentrations (GMR, 0.46; 90% CI, 0.33 to 0.63; P = 0.001), AUC(0-24) (GMR, 0.74; 90% CI, 0.64 to 0.86; P = 0.004), and half-life (GMR, 0.80; 90% CI, 0.75 to 0.86; P < 0.001) were also significantly reduced. The efavirenz half-life was significantly longer when it was coadministered with darunavir-ritonavir than when it was given alone (GMR, 1.66; 90% CI, 1.24 to 2.23; P = 0.01), but there were no differences in the efavirenz trough or peak concentration or AUC(0-24) when it was coadministered with darunavir-ritonavir. Efavirenz reduced the trough concentrations of darunavir significantly, but the concentrations remained above the EC(50) for the wild-type virus. This regimen should be evaluated with treatment-naïve patients with no preexisting resistance.
Soon
Gaik H
GH
National Healthcare Group, 6 Commonwealth Lane, Singapore 149547, Singapore.
Shen
Ping
P
Yong
Eu-Leong
EL
Pham
Paul
P
Flexner
Charles
C
Lee
Lawrence
L
D000328:Adult; D000368:Aged; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D048588:Benzoxazines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003521:Cyclopropanes; D000069454:Darunavir; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019438:Ritonavir / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013449:Sulfonamides / Q000008:administration & dosage / Q000493:pharmacokinetics*
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D013449:Sulfonamides; C098320:efavirenz; D019438:Ritonavir; D000069454:Darunavir
HIV Clin Trials. 2008 Nov-Dec;9(6):418-27
19203907
JAMA. 2008 Aug 6;300(5):555-70
18677028
Antimicrob Agents Chemother. 2009 Jun;53(6):2346-53
19223624
AIDS. 2009 Aug 24;23(13):1679-88
19487905
Clin Infect Dis. 2007 Nov 1;45(9):1230-7
17918089
Antimicrob Agents Chemother. 2008 Nov;52(11):3928-32
18725446
Antimicrob Agents Chemother. 2004 Nov;48(11):4476-8
15504888
J Clin Pharmacol. 2004 Nov;44(11):1273-81
15496645
Antivir Ther. 2010;15(2):275-9
20386083
Antimicrob Agents Chemother. 2003 Jan;47(1):350-9
12499212
AIDS. 2001 Jan 5;15(1):71-5
11192870
N Engl J Med. 2008 May 15;358(20):2095-106
18480202
Drugs. 2009;69(4):477-503
19323590
J Acquir Immune Defic Syndr. 2005 May 1;39(1):63-8
15851915
Antivir Ther. 2007;12(4):509-14
17668559
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 25;819(2):259-76
15833290
Rapid Commun Mass Spectrom. 2007;21(15):2505-14
17610214
Ann Intern Med. 2005 Nov 15;143(10):714-21
16287792
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Nov 15;859(2):234-40
17964231
Antimicrob Agents Chemother. 2005 Jun;49(6):2314-21
15917527